Colon Neuroendocrine Neoplasm
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A neoplasm with neuroendocrine differentiation that arises from the colon. It includes well differentiated neuroendocrine tumors (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade). 
There are 3 clinical trials for colon neuroendocrine neoplasm, of which 1 is open and 2 are completed or closed. Of the trials that contain colon neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (1 open).
SSTR2 is the most frequent gene inclusion criterion for colon neuroendocrine neoplasm clinical trials .
Pen-221 and pembrolizumab are the most common interventions in colon neuroendocrine neoplasm clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.